Product
Renvatinib
1 clinical trial
3 indications
Indication
Hepatocellular Carcinoma Non-resectableIndication
Portal Vein Tumor ThrombusIndication
Checkpoint InhibitorsClinical trial
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus#a Prospective, Multicenter, Single-arm Clinical StudyStatus: Recruiting, Estimated PCD: 2023-02-02